Paulson & Co’s Intersect ENT, Inc XENT Stock Holding History

Paulson & Co’s Portfolio XENT Stock Details XENT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-558,000	Closed	-$15.6M	–	97
2017 Q2	$15.6M	Sell	558,000 -82,100	-13%	-$1.86M	0.21%	48
2017 Q1	$11M	Buy	+640,100	New	+$8.97M	0.15%	54

Other funds holding XENT

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Paulson & Co's XENT Position: Q3 2017 in Review

Paulson & Co sold out of Intersect ENT, Inc (XENT) in Q3 2017, closing a stake of 558,000 shares — an estimated $15.6M sold.

Paulson & Co first reported a position in XENT in Q1 2017 and held it in 2 quarters. The position peaked at $15.6M in Q2 2017. 140 funds tracked by Wall St. Rank hold XENT as of Q3 2017.

Paulson & Co reported no remaining Intersect ENT, Inc position as of Q3 2017 after selling out during the quarter.
Paulson & Co sold 558,000 Intersect ENT, Inc shares in Q3 2017, an estimated $15.6M.
Paulson & Co first reported a position in Intersect ENT, Inc in Q1 2017 and held it in 2 quarters.
Paulson & Co's Intersect ENT, Inc position peaked at $15.6M in Q2 2017.
140 funds tracked by Wall St. Rank held Intersect ENT, Inc as of Q3 2017.

Based on Paulson & Co's 13F filing for Q3 2017, filed 14 Nov 2017.